The Personalized Medicine Initiative supports commercialization activities for implementation of personalized medicine. The PMI helps companies with product definition, market research, intellectual property consultation and protection, business plan development, project management and fundraising, nurturing the translation of promising technologies and services into commercial products to enhance human health and cultivate an ecosystem for personalized medicine.
Contextual Genomics is a privately held company launched in 2012 to develop and deliver genomic-based molecular diagnostics to cancer patients. Contextual Genomics is developing a suite of genomics based cancer tests to improve cancer prevention, treatment and monitoring. With deep expertise, multiple genomics-based cancer tests and strategic alliances in place, they are leading this shift towards personalized cancer care.
The vision of GenXys is to improve care for individual patients through the use of genomic information. Products will enable physicians and pharmacists to tailor advice to individuals using the GenXys clinical decision support systems in association with clinically effective genetic markers.
Microbiome Insights is a service company providing microbiome analysis for academic and industrial researchers. Microbiome Insights has the systems and expertise needed to add cutting edge microbiome analysis to your study.
Molecular You will use longitudinal, integrated Omics datasets to provide preventive insight and improve diagnosis and early disease detection. By establishing a baseline of a person’s molecular makeup and monitoring these data over time, trends towards health or disease can be detected, radically empowering people to take control over their own health.
Personalized Biomarkers Inc.
Personalized Biomarkers Inc. is dedicated to identifying and translating personalized approaches to managing and treating diabetes more effectively and safely. Identifying biomarkers for the development of diagnostics to guide prescription has the potential to reduce adverse drug reactions and improve outcomes, while saving patients and the healthcare system in avoidable ineffective prescribing and treatment of adverse drug reactions.
Acuitas Therapeutics is a biotechnology company that works with partners and customers to develop new or improved medicines based on internationally recognized capabilities in nanotechnology-based pharmaceutical product development. Acuitas provides delivery solutions for molecular therapeutics using lipid nanoparticles.
Cyon Therapeutics uses technology developed at the University of British Columbia to enhance the body’s ability to neutralize and clear bacterial toxins that cause sepsis.
“Reawakening your immune response against cancer”
ME Therapeutics develops drugs targeting immune cell dysfunction in cancer.
Mesentech Inc is developing novel therapeutics designed to accelerate bone healing and maintain bone health.
Primary Peptides develops innovative peptide drugs using protected platform technology focusing on severe diseases with large drug markets including cardiovascular disease, brain diseases and cancer.
Precision NanoSystems powers the development of precision medicine by providing scientists with an integrated platform of products and support, helping advance innovative nanotechnology solutions for the understanding of the molecular basis of disease.
Synaptitude Brain Health Inc. aims to bring revolutionary advances in brain imaging, genomics and neurocognitive assessments to the general public for the benefit of human brain health. Synaptitude combines sophisticated research and technical analyses to provide clients with the most comprehensive brain health assessments.